Sage Therapeutics Inc
(NAS:SAGE)
$
11.09
0.46 (4.31%)
Market Cap: 667.42 Mil
Enterprise Value: -72.17 Mil
PE Ratio: 0
PB Ratio: 0.95
GF Score: 46/100 Sage Therapeutics, Inc. Presents at Goldman Sachs 41st Annual Global Healthcare Conference, Jun-10-2020 12:00 PM Transcript
Jun 10, 2020 / 07:00PM GMT
Release Date Price:
$36.05
(-1.15%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Good afternoon. Thanks for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're pleased to have Sage Therapeutics with us.
And with that, I'm going to turn it over to Jeff Jonas, CEO, in the case he has any opening remarks.
Jeffrey M. Jonas
Sage Therapeutics, Inc. - CEO, President & Director
Well, first, thank you, Salveen. Thank you, Goldman. I hope everybody is well at home. And I just want to thank everyone for being here today, and I'll let you begin with questions.
Questions & Answers
Salveen Jaswal Richter;Jeffrey M. Jonas
Goldman Sachs Group, Inc., Research Division - VP
Perfect. So as you think about balancing the ZULRESSO launch here and the 3 new zuranolone indications that you're moving forward with on a pivotal standpoint, and then your -- rest of your R&D pipeline, 324, 718. What's the latest in portfolio management and maximizing capital efficiency here?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot